European Lifestars Awards - Celebrating Life Science Leaders’ Post

Well done Doug Lavender and Timothy Kilchenmann for organising such an insightful and inspirational event! And thank you for giving me the opportunity to be an active contributor this year. A few highlights from this 7th annual digital biomarkers in clinical trials summit : - the promise of precision psychiatry through digital phenotyping - mapping of 700+ speech variables: building blocks of novel endpoints in CNS - predictive/safety monitoring BMs for better oncology treatment outcomes - hormonal impact on Parkinson’s disease symptoms: inclusive research matters! - « digital paradox » in clinical research - nocturnal scratch DE validation journey continues under tech company’s leadership with DECODE - platform like DEEP: new WoW to simplify DE development, validation & qualification And some important reminders on best practices for DE development: - start with the why! What problem are you trying to solve? - if you want to go far, go together! And place the patient at the center of your collaboration. - engage regulators early on your validation plans.

The work on digital biomarkers never sits still, and every conference is expanding on experiences from case studies, methodologies, etc. Great summary from Aude Clement on the key takeaways from this event.

Our new #BrainHealthTimeMatters is now available: https://lnkd.in/eDavWAg So many have made this work possible. Our thanks go to Alexion Pharma Germany GmbH and Merck Healthcare for sponsoring the launch of this report and helping bring this work to all; to Roche, MS Society and Horizon, now part of Amgen for their critical support towards the development of the report; to the panel of authors Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, Giancarlo Comi, Kathy Costello, Michael Devlin, Jelena Drulovic, Emma Gray, Jodi Haartsen, Anne Helme, Jana Hlaváčová, Elisabeth Kasilingam, Yaou Liu, Thomas Mathew, Saul Reyes, Jérôme de Sèze and Mitzi Joi Williams M.D., FAAN and to the many members of the Working Groups named in the report who brought expertise and evidence to shape and support the recommendations. We thank you and look forward the next steps - collaborating with you and further stakeholders to support the implementation of the recommendations. #BrainHealthTM #BrainHealth #MSTimeMatters, #NMOSDTimeMatters, #MOGADTimeMatters, #MSBH #OHPF, The Sumaira Foundation, Sumaira Ahmed, EMSP - European Multiple Sclerosis Platform, MS International Federation (MSIF), Can Do MS

How can we strengthen the ROI of incorporating digital biomarkers in drug development trials and accelerate its adoption… looking forward to hearing the sessions today and sharing the insights! #DigitalBiomarkersSummit #medidata #clinicalinnovation

Out now: the updated 'MS Brain Health – time matters' report was launched at ECTRIMS yesterday! It highlights the importance of early diagnosis, timely treatment and holistic, person-centred care, along with the policy changes needed to improve long-term outcomes for those living with MS, NMOSD and MOGAD. #BrainHealthTM #BrainHealth #MSTimeMatters

It's webinar season at Norstella and we are hosting several open events to talk through our recent research reports and views of the industry. No speaking duties for me, but having seen snippets from each then I'm looking forward to making myself comfortable in the audience. Great opportunities to stay abreast of industry trends – whether your focus is in drug development, market access, or somewhere in between – and to get closer to the subject matter experts behind our brands. 💡 Pharma R&D Annual Review: May 21, 3pm BST/10am ET Ian Lloyd and Alexandra Shimmings, both of Citeline, continue their long-standing double act in reviewing the latest global R&D trends. Pipelines, approvals, emerging modalities, therapeutic areas, drug targets, leading sponsors, geographic hotspots and more - if you've seen any of the previous editions then you know not to miss this. https://lnkd.in/efECkPtd 💡 Overcoming the Barriers to Patient Access in 2024 and Beyond: May 21, 7pm BST/2pm ET If you are more focused on the latest commercial dynamics, then join Dinesh Kannan Kabaleeswaran and Jennifer (Goldenberg) Klarer, M.Sc.Eng. in this review of the latest patient access themes. MMIT (Managed Markets Insight & Technology) and The Dedham Group joined forces earlier in the year for a quantitative stakeholder survey, and this is our exclusive take on the results and implications for patient access, from pharma to payers and providers. https://lnkd.in/eTkwBerh 💡 Orphan Drugs - Are They Losing Their Sparkle: May 29, 3pm BST/10am ET Puru Gaur will give the lowdown from Evaluate Ltd's latest orphan drug deep dive, with Melanie Senior and Stephanie Leouzon debating the implications of an apparent slow down in sales growth. Does this indicate a drop in investor and pharma appetite for rare diseases, or is it just a case of maturity. And how do new technologies and legislation affect the balance? Join us to find out. https://lnkd.in/e_he3TQu

Register for tomorrow’s Webinar. Learn insights to help your team create trials that not only meet regulatory and scientific standards, but also align with the needs and experiences of patients.

🔍 Navigating the complexities of pharma deals? Join the 'Pharma Dealmakers Panel: Viewing the Challenges from Both Sides' at #Sachs_ELSF on February 29th, 2024, at the Hilton Zurich Airport Hotel. A deep dive into the intricacies of biopharma collaborations and negotiations. 🌐🤝 Chaired by: Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company Panellists: Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG David Colpman, Director, Alpina Life Science Advisors Emin Fadillioglu, MD, CEO, Eczacıbaşı Topluluğu Pharmaceutical and Industrial Investment Co. Peter L. Braun, CEO, TargImmune Therapeutics AG Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi Gain unparalleled insights into the challenges and strategies of pharma dealmaking from the perspectives of both biotech innovators and pharma giants. This panel is a must-attend for those looking to understand the dynamics of successful partnerships and investments in the rapidly evolving life sciences landscape. Don’t miss out on this opportunity to network with industry leaders and strategize for success. Register today at www.sachsforum.com/17elsf and be part of the conversation #inperson & #online during the Sachs Spring Life Sciences Week. #PharmaDealmakers #Biopharma #LifeSciences #StrategicPartnerships #InvestmentStrategies #BiotechInnovation #PharmaIndustry #SachsForum #Sachs_ELSF #SachsSpringLifeSciencesWeek #SSLSW

Please join me and many other Medical Affairs experts at the 16th annual #MedAffairs #Transformation conference on November 14 in Zurich, Switzerland. I'll share my perspectives on 'the impact of medical affairs on the corporate's mid and long-term strategy' and join a panel session to discuss 'the Impact of internal and external stakeholder value needs on Medical Affairs capabilities development' Please learn more about the program and find out how to register below. Looking forward to engaging discussions and catching up with friends! #ViaViatris #EvidenceLifeScience

WHO: Biotech and Pharma companies in the San Francisco Bay Area WHEN: 19 September, 12-2pm WHERE: The Lighthouse Cafe in Oyster Point WHAT: A Lunch & Learn event And most importantly... WHY: Meet with experts from across the Australian Clinical Trial Ecosystem and learn about the benefits of running early phase studies down there. REGISTER: https://lnkd.in/gYHT8g2P When runway is precious and efficiency is paramount, look to Australia to get your phase 1 study started sooner, completed promptly, and done less expensively. Return to the US IND process with your phase 1 complete and human data in hand and get a jumpstart on the coming biotech boom.